Advertisement

Acute Lymphoblastic Leukemia

  • Josep-Maria RiberaEmail author
Chapter

Abstract

The term “non-AIDS-defining cancers” (NADCs) refers to neoplasms other than AIDS-defining malignancies that occur in individuals with HIV infection. The spectrum and incidence of various neoplasms reported among persons infected with human immunodeficiency virus (HIV) has increased, and this emerging problem has contributed to the mortality of HIV-infected persons in the current era of potent antiretroviral therapy (ART). Large, population-based studies involving registry match data have reported a wide range of cancers in association with HIV infection. Incidence of cancer among HIV-infected persons was compared with that of the general population from 1992 to 2003 in a prospective observational study conducted in the United States. However, investigators reported that the incidence of leukemia was only slightly higher in HIV-infected people (standardized incidence ratio, SIR: 2.5; 95 % CI: 1.6–3.8). Except for a higher frequency of mature B or Burkitt’s ALL in HIV-infected patients, the clinical and biologic characteristics of ALL are similar to those observed in non-immunocompromised patients. In the ART era, the treatment of ALL in HIV-positive patients should be identical to that given in non-immunosuppressed individuals.

Keywords

Human Immunodeficiency Virus Acute Lymphoblastic Leukemia Human Immunodeficiency Virus Infection Minimal Residual Disease Standardize Incidence Ratio 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Funding

Supported in part by grants from the Red Temática de Investigación Cooperativa en Cáncer (RTICC, FEDER) (RD12/0036/0029); 2014 SGR225 (GRE) Generalitat de Catalunya; PI14/01971 from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III; and Fundació Internacional Josep Carreras i Obra Social “la Caixa,” Spain.

References

  1. 1.
    Pantanowitz L, Dezube BJ. Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS. 2009;4:27–34.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.CrossRefPubMedGoogle Scholar
  3. 3.
    Stebbing J, Duru O, Bower M. Non-AIDS-defining cancers. Curr Opin Infect Dis. 2009;22:7–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59:287–97.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Hagiwara S, Yotsumoto M, Odawara T, Ajisawa A, Uehira T, Nagai H, et al. Non-AIDS-defining hematological malignancies in HIV-infected patients: an epidemiological study in Japan. AIDS. 2013;27:279–83.CrossRefPubMedGoogle Scholar
  7. 7.
    Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013;57:756–64.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Cancer Statistics US Working Group. United States Cancer Statistics: 1999–2010 incidence and mortality web-based report. Atlanta: Department of Health and Human Services. Centers for Disease Control and Prevention, and National Cancer Institute; 2013. Available at: http://www.cdc.gov/uscs. [Last accessed 29 December 2014].Google Scholar
  9. 9.
    Rossi G, Gorla R, Cadeo GP, Stellini R, Marinone G. Acute lymphoblastic leukaemia of B cell origin in an anti-HIV positive intravenous drug abuser. Br J Haematol. 1988;68:140–1.CrossRefPubMedGoogle Scholar
  10. 10.
    Garavelli PL. Acute lymphoblastic leukemia, L3 type, in a HIV positive patient. Haematologica. 1988;73:89.PubMedGoogle Scholar
  11. 11.
    Brunet S, Rabella N, Aventín A, Soler J. Acute lymphoblastic leukemia of the Burkitt’s type in a patient seropositive for the human immunodeficiency virus. Med Clin (Barc). 1987;89:527.Google Scholar
  12. 12.
    Biggar RJ, Horm J, Goedert JJ, Melbye M. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol. 1987;126:578–86.PubMedGoogle Scholar
  13. 13.
    Berman M, Minowada J, Loew JM, Ramsey MM, Ebie N, Knospe WH. Burkitt cell acute lymphoblastic leukemia with partial expression of T-cell markers and subclonal chromosome abnormalities in a man with acquired immunodeficiency syndrome. Cancer Genet Cytogenet. 1985;16:341–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Monfardini S, Vaccher E, Pizzocaro G, Stellini R, Sinicco A, Sabbatani S, et al. Unusual malignant tumours in 49 patients with HIV infection. AIDS. 1989;3:449–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Pollock BH, Jenson HB, Leach CT, McClain KL, Hutchison RE, Garzarella L, et al. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003;289:2393–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Granovsky MO, Mueller BU, Nicholson HS, Rosenberg PS, Rabkin CS. Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute. J Clin Oncol. 1998;16:1729–35.PubMedGoogle Scholar
  17. 17.
    Moschovi M, Theodoridou M, Papaevangelou V, Tzortzatou-Stathopoulou F. Acute lymphoblastic leukaemia in an infant exposed to zidovudine in utero and early infancy. AIDS. 2000;14:2410–1.CrossRefPubMedGoogle Scholar
  18. 18.
    Lorenzon D, Perin T, Bulian P, De Re V, Caggiari L, Michieli M, et al. Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. Hum Pathol. 2009;40:1045–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bacci MR, Santos JA, Zing NC, Barros DM. Acute lymphocytic leukaemia and AIDS. BMJ Case Rep. 2013. doi: 10.1136/bcr-2013-010036.
  20. 20.
    Stefan DC, Dippenaar A, De Bruin G, Uys R, van Toorn R. Challenges to treatment of leukemia in HIV-positive children. J Trop Pediatr. 2012;58:521–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Ghosh M, Banerjee M, Chakraborty S, Bhattacharyya S. Successful outcome in a HIV infected child presenting with Pre-B Acute Lymphoblastic Leukemia. Indian J Pediatr. 2012;79:267–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Tomonari A, Takahashi S, Shimohakamada Y, Ooi J, Takasugi K, Ohno N, et al. Unrelated cord blood transplantation for a human immunodeficiency virus-1-seropositive patient with acute lymphoblastic leukemia. Bone Marrow Transplant. 2005;36:261–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Girmenia C, Gastaldi R, Martino P. Catheter-related cutaneous aspergillosis complicated by fungemia and fatal pulmonary infection in an HIV-positive patient with acute lymphocytic leukemia. Eur J Clin Microbiol Infect Dis. 1995;14:524–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Gérinière L, Bastion Y, Dumontet C, Salles G, Espinouse D, Coiffier B. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. Ann Oncol. 1994;5:437–40.PubMedGoogle Scholar
  25. 25.
    Turner ML, Watson HG, Russell L, Langlands K, Ludlam CA, Parker AC. An HIV positive haemophiliac with acute lymphoblastic leukaemia successfully treated with intensive chemotherapy and syngeneic bone marrow transplantation. Bone Marrow Transplant. 1992;9:387–9.PubMedGoogle Scholar
  26. 26.
    Batlle M, Ribera JM, Font A, Millà F. Burkitt-type acute lymphoblastic leukemia in a patient with human immunodeficiency virus infection. Sangre (Barc). 1991;36:249–50.Google Scholar
  27. 27.
    Pogliani EM, Rossini F, Pioltelli P, Lanzi E, Casaroli I, Bolis S, et al. A case of acute lymphoblastic leukemia in an anti-HIV positive patient. Allergol Immunopathol (Madr). 1991;19:103.Google Scholar
  28. 28.
    Mansberg R, Rowlings PA, Yip MY, Rozenberg MC. First and second complete remissions in a HIV positive patient following remission induction therapy for acute non-lymphoblastic leukaemia. Aust NZ J Med. 1991;21:55–7.CrossRefGoogle Scholar
  29. 29.
    Polizzotto MN, Skinner M, Cole-Sinclair MF, Opat SS, Spencer A, Avery S. Allo-SCT for hematological malignancies in the setting of HIV. Bone Marrow Transplant. 2010;45:584–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, et al. PETHEMA Group and German HIV Lymphoma Cohort. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55:2341–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12:905–12.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Corona G, Vaccher E, Spina M, Toffoli G. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin’s lymphoma. AIDS. 2013;27:1033–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21:445–54.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Stefan DC. Effect of HIV infection on the outcome of cancer therapy in children. Lancet Oncol. 2014;15:e562–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematol Am Soc Educ Prog. 2013;2013:382–8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Clinical Hematology DepartmentICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autònoma de BarcelonaBadalonaSpain

Personalised recommendations